China-based gene-editing therapeutics company developing potentially curative medicines for genetic and complex diseases
China-based gene-editing therapeutics company developing potentially curative medicines for genetic and complex diseases. Its pipeline focuses on blood and inherited eye disorders, including beta-thalassemia, alpha-thalassemia, and Usher syndrome, and is exploring cardiovascular, metabolic, infectious, and autoimmune diseases. The company uses genomic and AI-supported target discovery and CRISPR-based editing, including base editing, with ex vivo and in vivo delivery approaches such as LNPs andA